Investigation of the in vitro and in vivo therapeutic activity of Tarantula cubensis extract (Theranekron ® ) on Leishmania major.

BACKGROUND OBJECTIVES: Cutaneous leishmaniasis (CL) is a vector-borne parasitic disease caused by several species of the protozoan parasite Leishmania. The need for new anti-leishmanial drugs for the treatment of CL is highlighted by factors such as high cost, toxicity, potential for resistance and limited long-term use of existing anti-leishmanial drugs. The aim of this study was to investigate the therapeutic effect of Tarantula cubensis alcoholic extract (TCE), which has been shown to have wound-healing, anti-inflammatory, regenerative, resolving and epithelialising effects, on L. major promastigotes in vitro and in vivo in an experimental mouse model of CL. METHODS: The effect of TCE on L. major promastigotes in vitro was investigated after determination of non-cytotoxic concentrations of TCE using the XTT method. To establish a CL model, L. major amastigotes were injected into the paws of BALB/c mice. Lesion size and histopathological evaluation were used to assess the effect of treatment. RESULTS: TCE was found to be effective against L. major promastigotes at 24 h and 48 h at concentrations of 250 µg/mL, 125 µg/mL and 62.5 µg/mL ( P <0.05). TCE was found to be more effective than meglumine antimonate in treating CL in the experimentally induced CL model in BALB/c mice. INTERPRETATION CONCLUSION: The results suggest that TCE holds promising potential therapeutic agent for the treatment of CL. However, further extensive investigations are required to substantiate and expand understanding in this area.

Toxoplasma gondii and multiple sclerosis: a population-based case-control seroprevalence study, Central Anatolia, Turkey.

BACKGROUND: Toxoplasma gondii, an obligate intracellular parasite, is prevalent in various mammalian species, as well as certain avian, reptilian, and cold-blooded organisms. While immunocompetent individuals generally remain asymptomatic, immunocompromised individuals may experience severe and life-threatening conditions. Multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system (CNS), is characterized by inflammation, demyelination, and axonal damage. Despite extensive research, the etiology and pathogenesis of MS remain incompletely understood. Given the strong affinity of T. gondii for the CNS, researchers have explored the potential association between T. gondii and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, and MS. This study aimed to investigate the possible relationship between MS and T. gondii. METHODS: A population-based incident cohort of MS patients in Sivas, Turkey, was used to randomly select MS patients. Age- and sex-matched controls were also randomly selected from the general population. A total of 182 MS patients and 182 controls were included in the study. Clinical and socio-demographic variables were recorded using a structured questionnaire. Blood samples were collected from MS patients, and Toxoplasma IgG and IgM antibodies were measured using the enzyme-linked immunosorbent assay technique. RESULTS: Anti-Toxoplasma IgG antibodies were detected in 78 cases (42.9%) and 73 controls (40.1%) (p>0.05). Age, female sex, and consumption of raw meat were identified as risk factors for toxoplasmosis in both MS patients and controls. CONCLUSION: In contrast to previous studies, this study did not find a significant difference in T. gondii seropositivity between the control group and MS patients. Further investigations are recommended to elucidate the precise relationship between MS patients and T. gondii.

Esterification of Fructose-oleic Acid by tert-Butanol/Dimethyl Sulfoxide and by 2-Methyl-2-butanol/Dimethyl Sulfoxide.

In this study two different strategy were followed to obtain a D-fructose-oleic acid ester. One of the strategies has been well established enzymatic synthesis of an ester bond. The other strategy excluded the biocatalyst and only used a mixture of two organic solvents as the reaction media, 2-methyl-2-butanol / dimethyl sulfoxide or tert-butanol / dimethyl sulfoxide for the production of D-fructose-oleic acid ester. Ester products obtained were characterised by using FT-IR, NMR, by MS. Product yield was also assessed by HPLC. Results of structural analyses and yield measurement indicated that two approaches produced almost identical ester products.

A new therapeutic approach for the treatment of cutaneous leishmaniasis: Photothermal application of macrophage-specific antibody binding graphene oxide nanoparticles.

BACKGROUND & OBJECTIVES: Cutaneous leishmaniasis (CL) is a zoonotic and anthropogenic protozoal disease. We aimedto develop a new therapeutic approach for the treatment of CL. METHODS: BALB/c mice have infected L. major amastigotes from their footpads. Twenty-one days later after injection, the animals were divided into three control and three experimental groups. The intralesional injection of graphene oxide and photothermal application (GO+PA) were applied to the first experimental group (Group 1); graphene oxide modified with a macrophage-specific antibody and photothermal application (MSA+GO+PA) were applied to the second experimental group (Group 2), and the photothermal application (PA) was applied to the third experimental group (Group 3). Miltefosine was administered orally to the first control group (Group 4); the second control group that is not treated was assigned as the positive control (Group 5) and the third control group was assigned as the negative control (Group 6). Lesions were examined (erythema and edema) after the 5th day and 10th of the treatment, clinically. On the 10th day of the treatment, the level of TNF-α, IL-1, IL-6, and IFN-ɤ were detected histopathologically and immunohistochemically. RESULTS: In the 5th day of the treatment it was observed that 50% of the animals were completely treated with Group 2, and in the 10th day, the ration raised to 75%. INTERPRETATION & CONCLUSION: We showed a novel application to treat CL by using MSA modified GO and PA within 10 days. According to our study outcomes, this application could be a new treatment approach for CL cure.

Cytotoxic effect of acriflavine against clinical isolates of Acanthamoeba spp.

Acanthamoeba keratitis (AK) is a potentially devastating and sight-threatening infection of the cornea caused by the ubiquitous free-living amoebae, Acanthamoeba species. Its eradication is difficult because the amoebas encyst, making it highly resistant to anti-amoebic drugs. Acriflavine neutral (ACF) has been used for treatment of microbial infections for humans and fishes. The aim of our study was to evaluate the time-dependent cytotoxicities of ACF against Acanthamoeba spp. Trophozoites and cysts of three different strains (strain PAT06 Acanthamoeba castellanii, strain 2HH Acanthamoeba hatchetti, and strain 11DS A. hatchetti) of Acanthamoeba spp. were tested. All strains had been isolated from patients suffering from a severe AK. The effects of the ACF with the concentrations ranging from 15 to 500 mg mL(-1) on the cytotoxicity of Acanthamoeba strains were examined. ACF showed a time- and dose-dependent amebicidal action on the trophozoites and cysts. Pat06 (A. castellanii) was the most resistant, while strain 11DS (A. hatchetti) was the most sensitive. As a result, ACF could be concluded as a new agent for the treatment of Acanthamoeba infections. On the other hand, it still needs to be further evaluated by in vivo test systems to confirm the efficiency of its biological effect.